191 patents
Page 2 of 10
Utility
Selection of Improved Tumor Reactive T-cells
9 Feb 23
The present invention provides methods for preselecting TILs based on PD-1 expression, as well as methods for expanding those preselected PD-1 positive TILs in order to produce therapeutic populations of TILs with enhanced tumor-specific killing capacity (e.g., enhanced cytotoxicity).
Michelle Simpson-Abelson, Arvind Natarajan, Cecile Chartier-Courtaud, Matt Paulson
Filed: 4 Nov 19
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
2 Feb 23
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 15 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
26 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 30 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
26 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 30 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
26 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 30 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
19 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 1 Jul 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
19 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender
Filed: 30 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
12 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
3 Jan 23
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
22 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 1 Jul 22
Utility
Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
22 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 1 Jul 22
Utility
Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy
20 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
15 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 1 Jul 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
15 Dec 22
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Closed Process for Expansion and Gene Editing of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
15 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Cecile Chartier-Courtaud, Krit Ritthipichai
Filed: 1 Jul 22
Utility
Restimulation of Cryopreserved Tumor Infiltrating Lymphocytes
15 Dec 22
The present disclosure provides methods for re-stimulating TIL populations that lead to improved phenotype and increased metabolic health of the TILs and provides methods of assaying for TIL populations to determine suitability for more efficacious infusion after re-stimulation.
Ian Frank, Michael T. Lotze
Filed: 15 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22
Utility
Processes for Production of Tumor Infiltrating Lymphocytes and Uses of Same In Immunotherapy
8 Dec 22
The present invention provides improved and/or shortened methods for expanding TILs and producing therapeutic populations of TILs, including novel methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.
Seth Wardell, James Bender, Michael T. Lotze
Filed: 3 Aug 22